|
Biological Activity:
Dopamine D2 and 5-HT1A partial agonist in development as a potential treatment for schizophrenia and other psychotic indications; Pharmacoloy profile maskes it an atypical antipsychotic and a new approach for the treatment of schizophrenia.
References: online
DE Casey et al. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology 2008, 200, 317-331.
L Bardin et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav. Pharmacol. 2007, 18(2), 103–18.
Drugs Fut. 2006, 31(3), 268.
Chemical Name: 7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one methanesulfonate (1:1)
|